BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20 | -90.3% | 100 | 0.0% | 0.00% | – |
Q2 2023 | $206 | -37.6% | 100 | 0.0% | 0.00% | – |
Q1 2023 | $330 | +101.2% | 100 | 0.0% | 0.00% | – |
Q4 2022 | $164 | – | 100 | 0.0% | 0.00% | – |
Q3 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q2 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q1 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
Q4 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
Q3 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
Q2 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
Q1 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
Q4 2020 | $0 | -100.0% | 100 | 0.0% | 0.00% | -100.0% |
Q3 2020 | $2,000 | +100.0% | 100 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $1,000 | – | 100 | 0.0% | 0.00% | – |
Q1 2020 | $0 | – | 100 | 0.0% | 0.00% | – |
Q4 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
Q3 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
Q2 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
Q1 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
Q4 2018 | $0 | – | 100 | 0.0% | 0.00% | – |
Q3 2018 | $0 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
Ergoteles LLC | 124,329 | $472,000 | 0.01% |
CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |